Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. The biotech—which was launched into the ...

VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone beta receptor (TRβ) that possesses selectivity for liver tissue, as well as the beta receptor ...

The MarketWatch News Department was not involved in the creation of this content. 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 ...

SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...

The MarketWatch News Department was not involved in the creation of this content. Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau ...

Brian Lian, President and CEO, reported that "the Viking team continued to focus on execution of our core clinical strategy," emphasizing advancement of both oral and subcutaneous VK2735 programs. "We ...

Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a ...

Viking Therapeutics has completed enrollment in both Phase 3 VANQUISH trials for its injectable obesity drug VK2735 and now plans to start Phase 3 testing of its oral version in the fourth quarter of ...